We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

STJ:LSESt. James's Place Plc Analysis

Data as of 2026-03-14 - not real-time

£1,291.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

St. James's Place plc is trading at 1,291 p, just below its 20‑day SMA (1,293.8 p) and well under the 50‑day SMA (1,393.4 p), indicating a modestly bearish price position but a neutral overall trend. The RSI of 44.6 and a bullish MACD histogram (+4.8) suggest that downside momentum is easing and a short‑term upside could emerge, especially as the price approaches the identified support at 1,171 p. Fundamentals reinforce this view: the stock trades at a forward PE of 12.5 versus an industry average of 16.35, delivering an earnings‑yield advantage, while the dividend yield of 1.38% is supported by a low payout ratio of 18%, indicating sustainability. Recent analyst sentiment is positive, with UBS upgrading STJ to "buy" and setting a 12‑month target of 1,465 p, and consensus analysts project a mean target of 1,674 p—a roughly 30% upside from current levels. Volatility remains elevated at 57% over 30 days, yet the beta of 0.66 points to lower systematic risk, and the company’s strong ROE of 38.6% and solid cash generation underpin its resilience. In sum, the combination of undervaluation, improving technical signals, and a favorable dividend profile makes STJ an attractive candidate for investors seeking upside with manageable risk.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD histogram indicating early upside momentum
  • Price near technical support level (1,171 p) providing downside cushion
  • Recent UBS upgrade to "buy" adding analyst confidence

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE of 12.5 versus industry average of 16.35 suggesting valuation headroom
  • Consensus mean target price of 1,674 p implying ~30% upside
  • Sustainable dividend with low payout ratio enhancing total return

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong ROE of 38.6% reflecting efficient capital use
  • Robust operating and free cash flow supporting earnings stability
  • Asset‑management sector exposure with diversified global investments

Key Metrics & Analysis

Financial Health

Revenue Growth128.20%
Profit Margin1.76%
P/E Ratio13.0
ROE38.61%
ROA0.39%
Debt/Equity29.91
P/B Ratio452.7
Op. Cash Flow£1.1B
Free Cash Flow£769.0M
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI44.6
Support£1,171.00
Resistance£1,388.00
MA 20£1,293.83
MA 50£1,393.37
MA 200£1,299.85
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value£5,507.24
Target Price£1,673.96
Upside/Downside29.66%
GradeUndervalued
TypeBlend
Dividend Yield1.38%

Risk Assessment

Beta0.66
Volatility57.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.